

Experiment Number: 92013-03

Species/Strain: Rat/Fischer 344

P41: Terminal Sacrifice Clinical Chemistry Data

Date Report Requested: 10/24/2014

Time Report Requested: 11:13:42

First Dose M/F: NA / NA

Lab: NA

C Number: C92013

Cage Range: All

Date Range: All

Reasons For Removal: All

Removal Date Range: All

Treatment Groups: All

Study Gender: Both

Experiment Number: 92013-03

P41: Terminal Sacrifice Clinical Chemistry Data

Date Report Requested: 10/24/2014

Species/Strain: Rat/Fischer 344

Time Report Requested: 11:13:42

First Dose M/F: NA / NA

Lab: NA

MALE

Treatment Groups	Albumin g per dL	ALP IU per L	ALT IU per L	Bile Acids Per G Tissue umol per g	BUN mg per dL	Creatine Kinase IU per L
------------------	---------------------	-----------------	-----------------	--	------------------	-----------------------------

Day 93

0 ppm	4.9 ± 0.1	357.9 ± 113	56.8 ± 10.2	22.8 ± 10.4	22.9 ± 1.5	333.5 ± 130.4
625 ppm	5 ± 0.2	360.4 ± 101.2	59.9 ± 14.9	25.5 ± 12	22.8 ± 1.9	320.8 ± 133.2
1250 ppm	5 ± 0.2	373.7 ± 104.2	64.3 ± 10.5	29.2 ± 13.5	22.5 ± 1.4	362.4 ± 152.4
2500 ppm	4.9 ± 0.3	377.6 ± 95.3	90 ± 20.3	31.2 ± 16.2	22.4 ± 1.7	380.9 ± 166.9
5000 ppm	4.9 ± 0.2	389.6 ± 105.1	67 ± 21	26.4 ± 11.2	20.5 ± 1.3**	397.6 ± 131
10000 ppm	4.7 ± 0.3**	565.2 ± 157.5**	55.3 ± 17.5	43.3 ± 21.2**	21.2 ± 1.9**	333.5 ± 144.8

*p < 0.05

**p < 0.01

NOTE: Table is to include results for each time point samples were analyzed. Similar table is to be included for hematology parameters.

The values used in the calculations are the observations taken at the furthest point in the study for each subject (the greatest number of "days on study"). The "day" displayed is the maximum value of "days on study" across all subjects.

MALE

Treatment Groups	Creatinine U per L	Protein Total g per dL	SDH IU per L	Thyroid Stimulating Hormone ng per dL	Thyroxine ug per dL	Triiodothyronine ng per dL
------------------	-----------------------	---------------------------	-----------------	--	------------------------	-------------------------------

Day 93

0 ppm	0.6 ± 0.1	6.8 ± 0.3	24.4 ± 4.3	0.9 ± 1.2	3 ± 0.9	138.8 ± 15.4
625 ppm	0.6 ± 0.1	6.7 ± 0.4	25.6 ± 6.2	1.1 ± 0.7	3.1 ± 0.7	145.6 ± 15.9
1250 ppm	0.6 ± 0.1	6.9 ± 0.3	27.8 ± 4.8*	1 ± 0.7	2.8 ± 0.9	138.8 ± 16.5
2500 ppm	0.6 ± 0.1	6.7 ± 0.5	36.2 ± 10.6**	0.8 ± 0.5	2.6 ± 0.7	134.7 ± 14.1
5000 ppm	0.6 ± 0.1	6.8 ± 0.4	33 ± 12.7**	1.5 ± 1.2*	3.1 ± 0.9	134.8 ± 19.3
10000 ppm	0.6 ± 0.2	6.3 ± 0.4**	34.8 ± 4.3**	1.6 ± 0.9**	3.8 ± 0.5**	134.3 ± 15.5

*p < 0.05

**p < 0.01

NOTE: Table is to include results for each time point samples were analyzed. Similar table is to be included for hematology parameters.

The values used in the calculations are the observations taken at the furthest point in the study for each subject (the greatest number of "days on study"). The "day" displayed is the maximum value of "days on study" across all subjects.

Experiment Number: 92013-03

P41: Terminal Sacrifice Clinical Chemistry Data

Date Report Requested: 10/24/2014

Species/Strain: Rat/Fischer 344

Time Report Requested: 11:13:42

First Dose M/F: NA / NA

Lab: NA

FEMALE

Treatment Groups	Albumin g per dL	ALP IU per L	ALT IU per L	Bile Acids Per G Tissue umol per g	BUN mg per dL	Creatine Kinase IU per L
------------------	---------------------	-----------------	-----------------	--	------------------	-----------------------------

Day 93

0 ppm	4.9 ± 0.2	273.9 ± 67.5	43.2 ± 16.3	28.9 ± 18.6	23.6 ± 2.9	470.1 ± 175.7
625 ppm	4.9 ± 0.3	269 ± 56.4	50.8 ± 27.4	34.9 ± 17.7	22.9 ± 2.6	496.2 ± 187.5
1250 ppm	4.8 ± 0.7	296.7 ± 69.9	39.6 ± 18.1	38.8 ± 22.8	23.2 ± 2.4	402.2 ± 144.6
2500 ppm	4.8 ± 0.1	299.4 ± 61.4	50.4 ± 28.4	43.8 ± 25	22.9 ± 1.8	492.4 ± 172.6
5000 ppm	4.6 ± 0.2**	304.4 ± 48.3	38.7 ± 17.8	47.7 ± 18.5	21.1 ± 1.9	571.6 ± 313.7
10000 ppm	4.4 ± 0.2**	352.7 ± 48.9**	36.5 ± 9.8	27.3 ± 12.4	22.2 ± 2.7	580 ± 201.8

*p < 0.05

**p < 0.01

NOTE: Table is to include results for each time point samples were analyzed. Similar table is to be included for hematology parameters.

The values used in the calculations are the observations taken at the furthest point in the study for each subject (the greatest number of "days on study"). The "day" displayed is the maximum value of "days on study" across all subjects.

FEMALE

Treatment Groups	Creatinine U per L	Protein Total g per dL	SDH IU per L	Thyroid Stimulating Hormone ng per dL	Thyroxine ug per dL	Triiodothyronine ng per dL
------------------	--------------------	------------------------	--------------	---------------------------------------	---------------------	----------------------------

Day 93

0 ppm	0.6 ± 0.1	6.5 ± 0.5	20.3 ± 6.4	0.8 ± 0.6	3 ± 1.1	140.8 ± 14.2
625 ppm	0.6 ± 0.1	6.4 ± 0.5	22.9 ± 9.2	0.7 ± 0.7	2.6 ± 1.1	139.7 ± 20.2
1250 ppm	0.6 ± 0.1	6.3 ± 1	25.9 ± 7.9	0.8 ± 0.4	2.7 ± 0.9	142.1 ± 23
2500 ppm	0.7 ± 0.1	6.3 ± 0.2	24.3 ± 10.5	0.7 ± 0.4	2.1 ± 0.6	134.1 ± 15.3
5000 ppm	0.7 ± 0.1	6.3 ± 0.9*	21.6 ± 8.3	0.7 ± 0.5	2.7 ± 0.9	132.2 ± 16.8
10000 ppm	0.6 ± 0.1	5.9 ± 0.3**	23.3 ± 6.9	1 ± 0.6	2.2 ± 0.9*	127.7 ± 18.9*

** END OF REPORT **

*p < 0.05

**p < 0.01

NOTE: Table is to include results for each time point samples were analyzed. Similar table is to be included for hematology parameters.

The values used in the calculations are the observations taken at the furthest point in the study for each subject (the greatest number of "days on study"). The "day" displayed is the maximum value of "days on study" across all subjects.